NCT06362044Completed
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
The Frequency of uMRD in Japanese Patients With CLL After 24 Months of Treatment With Venetoclax±Rituximab in the 2L+ in the Real-World Setting
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan. Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan. Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 89 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 7 Jun 2023
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- AbbVie
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT06362044
What you commit to
- Study type: Observational
- Participants enrolled: 89
- From 7 Jun 2023 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No data on information on the start and end dates or continuation of treatment with Venetoclax.
Other
- Participating in other clinical trials.
Who the study is looking for
- Diagnosed with relapsed/refractory (2 Line \[2L\]+) chronic lymphocytic leukemia (CLL) in Japan based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria at the time of informed consent (IC).
- Treatment with Venetoclax±Rituximab for 24 months who are not treated with any other concurrent CLL treatment.
- Expected to visit the hospital at + 3 months after treatment with Venetoclax±Rituximab for 24 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center Hospital East /ID# 265970 Coordinator of this site? Confirm its status | Kashiwa-shi | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.